Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-microRNA-1271-5p
- Development stage
- Unknown
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Parenteral
01
Overview
Anti-microRNA-1271-5p refers to a class of synthetic antisense oligonucleotides designed to specifically bind and sequester mature microRNA-1271-5p (miR-1271-5p). By inhibiting the activity of miR-1271-5p, these agents prevent the miRNA from binding to its target messenger RNAs (mRNAs), thereby de-repressing the expression of those genes. miR-1271-5p has been implicated in various pathological processes, including oncogenesis, where it may act as an oncomiR in certain contexts (e.g., promoting proliferation or metastasis), and in inflammatory conditions like osteoarthritis. Research-grade versions are widely used in functional genomics to elucidate the role of miR-1271-5p in disease pathways.
- Other names
- anti-miR-1271-5panti-miR1271-5panti-miR 1271-5pmiR-1271-5p inhibitormiR1271-5p inhibitormiR 1271-5p inhibitorantagomir-1271-5pantagomir1271-5pantagomir 1271-5p
Beyond the preview
Go deeper on anti-microRNA-1271-5p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-microRNA-1271-5p.